AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04345731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over the counter drug labels
Description: A control condition based on the current standard OTC label and 3 experimental labels will be compared to identify OTC labels that more effectively communicate critical information for the reduction of adverse drug events to the consumer
Study NCT03579745 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lingual orthodontics
Description: A coil spring will be attached from the lever arm to the first molar tube
Study NCT03579745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual orthodontics
Description: A coil spring will be attached from the lever arm to the first molar tube
Study NCT01032967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: The patients will receive standard open esophagectomy with two-field lymphadenectomy
Study NCT01032967 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive chemoradiation
Description: 3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
Study NCT01155947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study NCT01155947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study NCT04642638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4800
Description: INO-4800 was administered ID on Day 0 and Day 28.
Study NCT01731444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Study NCT00802269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retinal laser photocoagulation
Description: Retinal laser photocoagulation using a 532 nm laser
Study NCT00802269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retinal laser photocoagulation
Description: Retinal laser photocoagulation using a 532 nm laser
Study NCT01485224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~* 8 additional weeks of treatment after the achievement of complete response~* 16 additional weeks of treatment after the achievement of partial response~* 24 weeks of treatment completed without response~* unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks.
Study NCT02205866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial Receptivity Array analysis of endometrial biopsy
Description: A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
Study NCT02205866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endometrial Receptivity Array analysis of endometrial biopsy
Description: A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
Study NCT01557452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients
Study NCT01328054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
Study NCT01328054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo matching lapatinib
Description: placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
Study NCT05424107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KIDMED
Description: Pre-and post-intervention evaluation of the adherence to the Mediterranean diet and its effect on prediabetic state, as well as, other anthropometric values.
Study NCT02277795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCirc
Description: Circumcision with the use of the AccuCirc device.
Study NCT00227656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2a
Description: Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.
Study NCT00227656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
Study NCT02128867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assisted Autogenic Drainage (AAD)
Study NCT02128867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bouncing and AAD
Study NCT02128867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bouncing
Study NCT03078803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: FMT delivered by colonoscopy and oral capsules
Study NCT03078803 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transfer of water only
Study NCT03565666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
Description: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
Study NCT03565666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iLet Bionic Pancreas insulin-only configuration with Fiasp
Description: iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
Study NCT03565666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT01292460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol/ FDC/ Placebo/ Tafluprost
Description: Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).
Study NCT01292460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol/ FDC/ Placebo/ Tafluprost
Description: Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00).
Study NCT02182960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup
Study NCT02182960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brufen syrup
Study NCT03070431 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-precision RT 5x5 Gy in 1 week
Description: Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
Study NCT04681274 — intervention group
Intervention type: DEVICE
Intervention: Image features extraction and clustering
Description: The image processing operations required for local content-based image feature extraction consist of two main tasks: 1) tiling the images in smaller VOIs, typically a small cube, whose size depends on the modality, on the image resolution and on the purpose of the content-based query, and 2) performing feature extraction operations on the VOIs.~The Feature Extraction Engine performs totally unsupervised, automatic and asynchronous extractions of features from the images, organizes and indexes them in a no-SQL database based on unique similarity metric. The results of this phase are a series of clusters of phenotype signatures.
Study NCT04681274 — intervention group
Intervention type: DEVICE
Intervention: Phenotype signature database building
Description: Since the clusters are self-organizing their pathophysiological meaning is not readily apparent and requires further analysis. The characterization of each cluster is performed by analyzing representative samples and their respective correlation with histopathology results. After a series of iterations, the clusters are organized to correlate with distinct tissue subtypes identified by their signature similarity. The final number of clusters is not known a priori and depends on the heterogeneity of the underlying imaging phenotypes.
Study NCT01463683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2XP HEPTAVAX™-II SC
Study NCT01463683 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 1XP HEPTAVAX™-II SC
Study NCT01463683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2XP HEPTAVAX™-II IM
Study NCT01016496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: action observation therapy
Description: 15 consecutive sessions of 18 minutes, plus repetition
Study NCT01016496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repetition of gestures
Description: 15 consecutive session of visual games, plus repetition of gestures
Study NCT01956227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: exercise to look at balance and lower limb strength record in diary
Study NCT01956227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: sessions to discuss self-management ideas to modify risk of falling
Study NCT01956227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise plus Education
Description: combination of exercise sessions with education sessions to modify fall risk
Study NCT03536819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Votiva
Description: The applicator uses radio-frequency energy to treat the vaginal canal
Study NCT03586830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 1
Description: Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.
Study NCT03586830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 2
Description: Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.
Study NCT03586830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111 Dose Level 3
Description: Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.
Study NCT03586830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
Study NCT03158428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170202AA
Description: A moist snuff product
Study NCT03158428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSD170202AB
Description: A moist snuff product
Study NCT01000857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR and Paroxetine IR
Description: Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
Study NCT00527397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-464,005
Description: Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
Study NCT00527397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-464,005
Description: Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
Study NCT04211272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan will be administrated as film-coated tablet in Part A and Part B.
Study NCT04211272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil will be administrated as film-coated tablet in Part A.
Study NCT03055780 — intervention group
Intervention type: DEVICE
Intervention: CT-FFR. CTA. FFR
Description: Study is to compare results of CT FFR against CTA and interventional FFR
Study NCT04298970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Freeze-dried Brassica oleracea var. acephala
Study NCT04298970 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product
Study NCT04211272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: Riociguat will be administrated as film-coated tablet in Part A.
Study NCT04178460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib combined with MGD013
Description: The dose escalation part will enroll about 9 - 24 Gastric cancer (including gastroesophageal junction cancer) subjects, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level.~For the dose expansion part, patients with advanced or metastatic Gastric cancer (including gastroesophageal junction cancer), Triple negative breast cancer, Biliary tract carcinoma, Endometrial carcinoma will be enrolled, about 35 subjects for each expansion cohort during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation).
Study NCT04211272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin will be administrated as film-coated tablet in Part B.
Study NCT01387308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 50 mg x 2, single dose
Study NCT01387308 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fostamatinib
Description: Oral tablets, 50 mg x 3, single dose
Study NCT01387308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 100 mg, single dose
Study NCT01387308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Oral tablets, 150 mg, single dose
Study NCT03137641 — intervention group
Intervention type: OTHER
Intervention: Nurses urine samples
Description: Collected urine samples from nurses in contact with antineoplastic drugs.
Study NCT04344483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine and 1:100,000 Adrenaline
Description: Topical application of 2% Lidocaine and 1:100,000 Adrenaline in the form of dressing will be applied over skin graft donor site of thigh for 10 minutes.
Study NCT04344483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Topical application of Normal saline will be applied over skin graft donor site of thigh as a control group.
Study NCT02940756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine
Description: Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
Study NCT02940756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Description: Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to \<15 kg, two tablets twice daily for those weighing 15 to \<25 kg and three tablets twice daily for those weighing 25 to \< 35 kg, for three days.
Study NCT02940756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinine-piperaquine
Description: Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to \<7 kg, one tablet once daily for those weighing 7 to \<13 kg, and two tablets once daily for those weighing 13 to \<24 kg, for three days.
Study NCT00902772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: mg, oral dose
Study NCT00902772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: mg, oral dose
Study NCT00902772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04642638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
Study NCT04005105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive management
Description: Management based on premorbid MAP and MPP
Study NCT04642638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
Study NCT04642638 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
Study NCT00298428 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood samples
Description: blood samples before percutaneous coronary intervention (PCI) and at 4 months
Study NCT04046874 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Usual Care
Description: Pain Medication, imaging, referrals to other health services, other health care appointments
Study NCT04046874 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SPLIT Stratified Model of Care
Description: Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
Study NCT01782989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORACEA®
Description: ORACEA® (40mg doxycycline) capsule daily for 24 months
Study NCT01782989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule daily for 24 months
Study NCT04464304 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Smartphone
Description: Patients will participate in a similar game to the VR cohort, but will use a smartphone device.
Study NCT04464304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (Oculus Quest)
Description: Patients will participate in a game using VR.
Study NCT02443181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: Implementation of closed loop DBS for essential tremor
Study NCT02633384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
Study NCT02633384 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lipofundin
Description: Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
Study NCT01360359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization
Description: 3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning.
Study NCT01360359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk Motion and Fitness
Description: 3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises
Study NCT03137147 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention for Sleep and Pain in Youth
Description: See arm description.
Study NCT02997358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 75 mg/m² Day 1 of each 3-weeks cycle
Study NCT02997358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75 mg/m² Day 1 of each 3-weeks cycle
Study NCT02997358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: 150 μg/m²/day s.c From day 3 to day 9
Study NCT01707602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INTANZA® 15
Description: intradermal vaccination
Study NCT01707602 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip®
Description: Intramuscular vaccination
Study NCT01707602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INTANZA® 15 T
Description: transcutaneous vaccination